Spurious hyperphosphatemia in patients on hemodialysis with catheters.
作者信息
Schiller Brigitte, Virk Bhupinder, Blair Martin, Wong Amy, Moran John
机构信息
Satellite Laboratory Services, Redwood City, CA 94063, USA.
出版信息
Am J Kidney Dis. 2008 Sep;52(3):617-20. doi: 10.1053/j.ajkd.2008.03.033. Epub 2008 Jun 5.
Abstract
摘要
相似文献
1
Spurious hyperphosphatemia in patients on hemodialysis with catheters.血液透析患者使用导管时出现的假性高磷血症。
Am J Kidney Dis. 2008 Sep;52(3):617-20. doi: 10.1053/j.ajkd.2008.03.033. Epub 2008 Jun 5.
2
Alteplase as hemodialysis catheter locking solution and spurious hyperphosphatemia.阿替普酶作为血液透析导管封管溶液与假性高磷血症
J Vasc Access. 2011 Jul-Sep;12(3):269. doi: 10.5301/JVA.2011.6220.
3
Spurious hyperphosphatemia in a patient with alteplase-locked central venous catheter.阿替普酶封堵中心静脉导管患者的假性高磷血症
Pediatr Nephrol. 2006 Feb;21(2):301-2. doi: 10.1007/s00467-005-2088-1. Epub 2005 Dec 3.
4
Spurious Hyperphosphatemia in a Patient with Chronic Kidney Disease - a Rare Case of Alteplase Contamination.慢性肾脏病患者的假性高磷血症——阿替普酶污染的罕见病例。
Clin Lab. 2024 Apr 1;70(4). doi: 10.7754/Clin.Lab.2023.231101.
5
Predicting tissue plasminogen activator use and success in in-center hemodialysis patients.预测中心血液透析患者组织型纤溶酶原激活剂的使用情况及治疗效果
J Vasc Access. 2018 Mar;19(2):146-152. doi: 10.5301/jva.5000785. Epub 2018 Feb 19.
6
Comparison of intensive versus standard hemodialysis central venous catheter dysfunction protocol using rt-PA: a quality assurance initiative.使用rt-PA的强化与标准血液透析中心静脉导管功能障碍处理方案的比较：一项质量保证举措。
J Vasc Access. 2016 Mar-Apr;17(2):143-50. doi: 10.5301/jva.5000501. Epub 2016 Feb 5.
7
Prevention of dialysis catheter malfunction with recombinant tissue plasminogen activator.用重组组织型纤溶酶原激活剂预防透析导管故障。
N Engl J Med. 2011 Jan 27;364(4):303-12. doi: 10.1056/NEJMoa1011376.
8
The efficacy and safety of reteplase for thrombolysis of hemodialysis catheters at a community and academic regional medical center.瑞替普酶用于社区及学术性区域医疗中心血液透析导管溶栓的疗效与安全性。
Nephron Clin Pract. 2004;96(2):c39-42. doi: 10.1159/000076397.
9
Tissue plasminogen activator use in maintaining patency in hemodialysis access catheters.
Am J Kidney Dis. 2001 Feb;37(2):453-4. doi: 10.1053/ajkd.2000.22466.
10
Efficacy, safety, and cost of thrombolytic agents for the management of dysfunctional hemodialysis catheters: a systematic review.溶栓药物治疗功能失调性血液透析导管的疗效、安全性和成本：系统评价。
Pharmacotherapy. 2011 Oct;31(10):1031-40. doi: 10.1592/phco.31.10.1031.
引用本文的文献
1
Pseudohyperphosphatemia due to contamination with heparin: A case for caution.肝素污染导致的假性高磷血症：需谨慎对待的病例
Indian J Nephrol. 2014 Nov;24(6):409-10. doi: 10.4103/0971-4065.133040.
2
Hyperphosphataemia: treatment options.高磷血症：治疗选择。
Drugs. 2013 May;73(7):673-88. doi: 10.1007/s40265-013-0054-y.
本文引用的文献
1
Spurious hyperphosphatemia in a patient with alteplase-locked central venous catheter.阿替普酶封堵中心静脉导管患者的假性高磷血症
Pediatr Nephrol. 2006 Feb;21(2):301-2. doi: 10.1007/s00467-005-2088-1. Epub 2005 Dec 3.
2
Mineral metabolism, mortality, and morbidity in maintenance hemodialysis.维持性血液透析中的矿物质代谢、死亡率和发病率
J Am Soc Nephrol. 2004 Aug;15(8):2208-18. doi: 10.1097/01.ASN.0000133041.27682.A2.
3
Determinants of progressive vascular calcification in haemodialysis patients.血液透析患者血管钙化进展的决定因素
Nephrol Dial Transplant. 2004 Jun;19(6):1489-96. doi: 10.1093/ndt/gfh125. Epub 2004 Apr 21.
4
Spurious hyperphosphatemia due to sample contamination with heparinized saline from an indwelling catheter.
Clin Chem Lab Med. 2004 Jan;42(1):107-8. doi: 10.1515/CCLM.2004.021.
5
Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: a national study.慢性血液透析患者血清磷及钙磷乘积与死亡风险的关联：一项全国性研究
Am J Kidney Dis. 1998 Apr;31(4):607-17. doi: 10.1053/ajkd.1998.v31.pm9531176.
6
Pseudohyperphosphatemia.
Clin Biochem. 1995 Aug;28(4):391-3. doi: 10.1016/0009-9120(95)00013-y.
7
Pseudohyperphosphataemia incidence in an automatic analyzer.
Eur J Clin Chem Clin Biochem. 1994 Jul;32(7):559-61.
8
Hyperphosphatemia in multiple myeloma due to a phosphate-binding immunoglobulin.
Cancer. 1991 Sep 1;68(5):1092-4. doi: 10.1002/1097-0142(19910901)68:5<1092::aid-cncr2820680531>3.0.co;2-i.
Zotero 插件